MgSO4 vs Metoclopramide for Headache in Pregnant Women (MagHead)
Primary Purpose
Headache
Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
magnesium sulfate
metoclopramide
Sponsored by
About this trial
This is an interventional treatment trial for Headache focused on measuring pregnant women
Eligibility Criteria
Inclusion Criteria:
- Pregnant, 18-75
- Headache rated 4 or greater on a 0-10 pain scale
Exclusion Criteria:
- New objective neurologic abnormality at the time of exam
- Temperature >100.4
- Allergy or intolerance to study medications
- Suspected of confirmed preeclampsia/eclampsia
- Complete heart block
- Hypotension, SBP<85
- Myasthenia gravis
- End stage renal failure
Sites / Locations
- Women and Infants Hospital of Rhode Island
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Arm 1
Arm 2
Arm Description
magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
Outcomes
Primary Outcome Measures
The study will compare effectiveness of intravenous magnesium sulfate to that of intravenous metoclopramide (Reglan®) for acute headache in pregnant women.
Secondary Outcome Measures
Full Information
NCT ID
NCT00632606
First Posted
February 29, 2008
Last Updated
December 21, 2012
Sponsor
Women and Infants Hospital of Rhode Island
1. Study Identification
Unique Protocol Identification Number
NCT00632606
Brief Title
MgSO4 vs Metoclopramide for Headache in Pregnant Women
Acronym
MagHead
Official Title
Magnesium Sulfate vs Metoclopramide for Headache in Pregnant Women
Study Type
Interventional
2. Study Status
Record Verification Date
December 2012
Overall Recruitment Status
Withdrawn
Study Start Date
August 2008 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Women and Infants Hospital of Rhode Island
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study will compare effectiveness of intravenous magnesium sulfate to that of intravenous metoclopramide (Reglan®) for acute headache in pregnant women. We will randomize pregnant women who present to our emergency department with chief complaint of headache to magnesium sulfate 2 grams intravenously or metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally and normal saline 1 liter intravenously. Headaches are common during pregnancy, related to hormonal changes, altered sleep patterns and psychosocial stressors. Common medications for headache such as non-steroidal antiinflammatories or triptans are typically avoided during pregnancy due to concern for fetal effects. Women, and their physicians, are often uncertain regarding available medication options with justifiable safety profiles during pregnancy.
Detailed Description
Metoclopramide and prochlorperazine (Compazine®), antiemetic dopamine receptor antagonists, are widely used for headache treatment in North American emergency departments. Metoclopramide, FDA pregnancy category B, is used in clinical practice for acute headache in pregnant women. Small studies have found magnesium sulfate to be effective in migraine, tension and cluster headaches, although there is no data regarding efficacy or tolerability in pregnant women.
Our study would be similar to a Turkish study published in 2004 which compared magnesium sulfate to metoclopramide for acute headache treatment in nonpregnant individuals; they found the drugs equally effective 30 minutes after administration. Serum magnesium levels in pregnant women are often lower than in nonpregnant women; magnesium deficiency has been explored as contributing to headache frequency and severity. Magnesium sulfate use has been well established during pregnancy for decades, administered intravenously to delay labor or to women with preeclampsia for 24 to 48 hours, initially with 4 to 6 gram bolus then 2 grams per hour. For headache treatment, magnesium sulfate dose would be far lower, 2 grams. We would like to determine the efficacy and tolerability of magnesium sulfate for headache relief in pregnant women, as well as evaluate efficacy of metoclopramide in pregnant women. We do not find published randomized trials evaluating headache treatment in pregnant women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache
Keywords
pregnant women
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Active Comparator
Arm Description
magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
Arm Title
Arm 2
Arm Type
Active Comparator
Arm Description
metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
Intervention Type
Drug
Intervention Name(s)
magnesium sulfate
Intervention Description
magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Intervention Type
Drug
Intervention Name(s)
metoclopramide
Other Intervention Name(s)
Reglan
Intervention Description
metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Primary Outcome Measure Information:
Title
The study will compare effectiveness of intravenous magnesium sulfate to that of intravenous metoclopramide (Reglan®) for acute headache in pregnant women.
Time Frame
1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant, 18-75
Headache rated 4 or greater on a 0-10 pain scale
Exclusion Criteria:
New objective neurologic abnormality at the time of exam
Temperature >100.4
Allergy or intolerance to study medications
Suspected of confirmed preeclampsia/eclampsia
Complete heart block
Hypotension, SBP<85
Myasthenia gravis
End stage renal failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Meghan Hayes, MD
Organizational Affiliation
Women and Infants Hospital of Rhode Island
Official's Role
Principal Investigator
Facility Information:
Facility Name
Women and Infants Hospital of Rhode Island
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02905
Country
United States
12. IPD Sharing Statement
Learn more about this trial
MgSO4 vs Metoclopramide for Headache in Pregnant Women
We'll reach out to this number within 24 hrs